Clinical Trials Directory

Trials / Completed

CompletedNCT05984615

Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients

Status
Completed
Phase
—
Study type
Observational
Enrollment
1,961 (actual)
Sponsor
Novartis Pharmaceuticals · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This was a retrospective real-world evidence cohort study.

Conditions

Timeline

Start date
2022-06-08
Primary completion
2022-08-24
Completion
2022-08-24
First posted
2023-08-09
Last updated
2023-08-09

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05984615. Inclusion in this directory is not an endorsement.

Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma (NCT05984615) · Clinical Trials Directory